Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies
Under an Elsevier user license
open archive
Keywords
Lymphangioleiomyomatosis
Lymphatics
Metastasis
Mammalian target of rapamycin (mTOR)
Tuberous sclerosis complex (TSC)
Sirolimus
Cited by (0)
- d
Tel.: +1 (301) 402 8397; fax: +1 (301) 496 2363.
- e
Tel.: +1 (301) 402 7466; fax: +1 (301) 496 2363.
- f
Tel.: +1 (301) 451 4950; fax: +1 (301) 496 2363.
- g
Tel.: +1 (301) 594 5705; fax: +1 (301) 496 2363.
- h
Tel.: +1 (301) 402 0592; fax: +1 (301) 496 2363.
- i
Tel.: +1 (301) 594 7670; fax: +1 (301) 496 2363.
- j
Tel.: +1 (617) 919 2207; fax: +1 (617) 730 0231.
- k
Tel.: +1 (301) 295 3528; fax: +1 (301) 295 3150.
Copyright © 2010 Published by Elsevier Ltd.